1. A phase I/II study of the protease inhibitor ritonavir in children with human immunodeficiency virus infection
- Author
-
Mueller, Brigitta U., Nelson, Robert P., Jr., Sleasman, John, Zuckerman, Judy, Heath-Chiozzi, Margo, Steinberg, Seth M., Balis, Frank M., Brouwers, Pim, Hsu, Ann, Saulis, Rima, Sei, Shizuko, Wood, Lauren V., Zeichner, Steve, Katz, T. Teresa K., Higham, Colleen, Aker, Diane, Edgerly, Maureen, Jarosinski, Paul, Serchuck, Leslie, Whitcup, Scott M., Pizzuti, David, and Pizzo, Philip A.
- Subjects
HIV infection in children -- Drug therapy ,Ritonavir -- Evaluation ,Pharmacokinetics -- Research ,Drug therapy, Combination -- Evaluation - Abstract
Ritonavir may be effective and well-tolerated in children infected with HIV. Ritonavir is a protease inhibitor drug used to treat HIV-infected adults. Researchers evaluated the safety and effectiveness of ritonavir in 48 children, aged 6 months to 14.4 years. Ritonavir therapy resulted in an average increase in the CD4 white blood cell count of 79 cells per cubic millimeter, and a decrease in blood levels of the virus. Gastrointestinal complaints were the most common side-effects. Ritonavir may be an appropriate component of combination drug therapy in pediatric HIV disease., Background. Ritonavir, a potent antiretroviral protease inhibitor, has been approved for the treatment of adults and children with human immunodeficiency virus (HIV) infection. In a phase I/II study, we assessed the safety, tolerability, and pharmacokinetic profile of the oral solution of ritonavir in HIV-infected children and studied the preliminary antiviral and clinical effects. Methods. HIV-infected children between 6 months and 18 years of age were eligible. Four dose levels of ritonavir oral solution (250, 300, 350, and 400 mg/[m.sup.2] given every 12 hours) were evaluated in two age groups ([is less than or equal to] 2 years, [is greater than] 2 years). Ritonavir was administered alone for the first 12 weeks and then in combination with zidovudine and/or didanosine. Clinical and laboratory parameters were monitored every 2 to 4 weeks. Results. A total of 48 children (median age, 7.7 years; range, 0.5 to 14.4 years) were included in this analysis. Dose-related nausea, diarrhea, and abdominal pain were the most common toxicities and resulted in discontinuation of ritonavir in 7 children. Ritonavir was well absorbed at all dose levels, and plasma concentrations reached a peak 2 to 4 hours after a dose. CD4 cells counts increased by a median of 79 cells/[mm.sup.3] after 4 weeks of monotherapy and were maintained throughout the study. Plasma HIV RNA decreased by 1 to 2 [log.sub.10] copies/mL within 4 to 8 weeks of ritonavir monotherapy, and this level was sustained in patients enrolled at the highest dose level of 400 mg/[m.sup.2] for the 24-week period. Conclusions. The oral solution of ritonavir has potent antiretroviral activity as a single agent and is relatively well tolerated by children when administered alone or in combination with zidovudine or didanosine. Pediatrics 1998;101:335-343, protease inhibitor, child, HIV-1, CD4 cells, HIV RNA, pharmacokinetics., As of December 1996, [is greater than] 7600 children have been diagnosed with acquired immunodeficiency syndrome (AIDS) in the United States.[1] Approved treatment options for human immunodeficiency virus (HIV)-infected children [...]
- Published
- 1998